Basilea has signed an in-licensing agreement with ArQule for late-stage oncology asset derazantinib (ARQ 087), a small molecule that targets the fibroblast growth factor receptor (“FGFR”) family of kinases. Derazantinib is in Phase II development for second-line intrahepatic cholangiocarcinoma (“iCCA”), a rare cancer with limited treatment options and a poor prognosis. Under the terms of the deal, Basilea will pay $10m upfront and up to $326m in milestones. We estimate
04 May 2018
Derazantinib deal adds third oncology asset
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Derazantinib deal adds third oncology asset
Basilea Pharmaceutica AG (0QNA:LON) | 4,620 0 0.0% | Mkt Cap: 605.3m
- Published:
04 May 2018 -
Author:
Brigitte de Lima, PHD CFA -
Pages:
15
Basilea has signed an in-licensing agreement with ArQule for late-stage oncology asset derazantinib (ARQ 087), a small molecule that targets the fibroblast growth factor receptor (“FGFR”) family of kinases. Derazantinib is in Phase II development for second-line intrahepatic cholangiocarcinoma (“iCCA”), a rare cancer with limited treatment options and a poor prognosis. Under the terms of the deal, Basilea will pay $10m upfront and up to $326m in milestones. We estimate